YEAR2025
- Hepanamin® capsules (70 mg) completed three batches of 48-month long-term stability testing, confirming a 4-year shelf life.
- Selected in the “2025 Top 100 Taiwan Companies by Foreign Investors” and received three major awards: Mid-Tier High-Potential Enterprise Award, Top 10 Growth Award, and Top 10 Profitability Award.
YEAR2024
- SR-T100 injection submitted to the Ministry of Health and Welfare for consultation regarding human clinical trials.
YEAR2023
- G&E Biotech signed an exclusive Taiwan distribution agreement for “Miao Jing-Liang” with Golden Phoenix International Enterprise Co., Ltd.
- Hepanamin® received the “Malaysia Health Brand Award” in Malaysia.
- Received the National Pharmaceutical Technology Research and Development Award from the Ministry of Economic Affairs and the Department of Health.
YEAR2022
- Shortlisted for the Drug Technology Development Award by the Ministry of Health and Welfare.
- G&E Biotech signed a global exclusive distribution agreement for Hepanamin® with Ba Ma International.
YEAR2021
- Chairman, 12th Kaohsiung Medical University Pharmacy Educational Foundation.
- G&E Biotech signed a memorandum of understanding with Japan S-Link Co., Ltd.
- The new drug development project “Phase III clinical trial in Taiwan of SR-T100 gel for the treatment of cutaneous squamous cell carcinoma in situ (actinic keratosis)” was recognized by the Ministry of Economic Affairs A+ Corporate Innovation Program as a continuing exemplary case.
YEAR2020
- G&E Biotech signed a product sales cooperation agreement with Taiwan New Sound Broadcasting Co., Ltd.
- The new drug development project “Preclinical pharmacology and dose evaluation of SR-T100 injection for the treatment of malignant ascites in ovarian cancer” was approved by the Small and Medium Enterprise Administration of the Ministry of Economic Affairs with a subsidy covering 50% of the total project cost.
- The food plant obtained Ministry of Health and Welfare approval as a PIC/S GMP pharmaceutical plant also licensed to manufacture food products.
YEAR2019
- The Ministry of Health and Welfare approved SR-T100 ointment for Phase II clinical trials in Taiwan.
- The PIC/S GMP formulation plant was approved by the Ministry of Health and Welfare.
- Granted a pharmaceutical invention patent by the European Patent Office for a drug to treat or prevent skin aging and inflammation.
- Chairman Kuo Kuo-Hua was elected Executive Director and Vice Chairman of the Taiwan Bio Industry Organization.
- Hepanamin® was exported to Singapore, marking the company’s first step into international markets.
- G&E Biotech signed a distribution agreement for Hepanamin® with Eastern Tian-Mei Direct Selling Co., Ltd.
YEAR2018
- Construction of the new PIC/S GMP formulation plant was completed and passed on-site inspection by the Ministry of Health and Welfare.
- The U.S. FDA approved SR-T100 ointment for Phase II clinical trials in the United States.
YEAR2017
- Granted a pharmaceutical invention patent by the Malaysian government for a drug to treat viral warts.
- Chairman Kuo Kuo-Hua received the Outstanding Alumnus Award from the School of Pharmacy, Kaohsiung Medical University.
YEAR2016
- Granted pharmaceutical invention patents for a drug to treat viral warts by the Australian Patent Office and the government of Mainland China.
- The final report of the Phase III clinical trial of SR-T100 was reviewed and approved by the Ministry of Health and Welfare.
YEAR2015
- Granted pharmaceutical invention patents by the governments of Japan and the Republic of China (Taiwan) for a drug to treat or prevent skin aging and inflammation.
YEAR2014
- Granted pharmaceutical invention patents by the governments of Korea, Australia, and Russia for a drug to treat or prevent skin aging and inflammation.
- Granted pharmaceutical invention patents by the governments of Japan, Singapore, and Canada for a drug to treat viral warts.
- The new drug development project “Clinical trial of SR-T100 gel for the treatment of external genital warts” received a subsidy covering 45% of project costs from the Ministry of Economic Affairs.
YEAR2013
- Obtained domestic drug licenses for “Gan-Huo-Su Capsules 150 mg”, “Hepanamin® Capsules 70 mg”, and “Kang-Ai Xin-Gan Capsules”.
- Obtained domestic medical device licenses for wound dressings “Si-Mi Gel” and “You-Le Gel”.
- Granted pharmaceutical invention patents for viral wart treatment by Taiwan, Australia, and New Zealand.
- Granted pharmaceutical invention patents by the governments of the United States and New Zealand for a drug to treat or prevent skin aging and inflammation.
YEAR2012
- Received the Gold Award in the “2011 Drug Technology Research and Development Awards” organized by the Food and Drug Administration and the Ministry of Economic Affairs.
- Granted a pharmaceutical invention patent for viral wart treatment by the South African government.
YEAR2011
- The company’s patent received the Gold Medal in the 2011 National Invention and Creation Awards.
- Recognized by the Department of Industrial Technology, Ministry of Economic Affairs, for industrial innovation achievements in 2011.
- The Department of Health approved SR-T100 (renamed SR-T200) for pilot clinical trials in vulvar cancer and other skin diseases at National Cheng Kung University Hospital.
- Received the Technology Innovation Achievement Award from the Department of Industrial Technology, Ministry of Economic Affairs.
YEAR2010
- Collaborated with National Cheng Kung University on the national biotech pharmaceutical program “Candidate Botanical New Drug SR-100”.
- Awarded the SNQ (Symbol of National Quality) certification.
- Recognized as an Outstanding Enterprise in Tainan.
- Received the Gold Award at the 2010 Taipei Biotech Awards and the Gold Award at the Taiwan Biomedical & Agri-Biotech Competition.
YEAR2009
- Obtained invention patents from the European Union and Canada.
- Completed patient enrollment for the Phase II clinical trial in actinic keratosis.
- The Chairman received the 17th Industrial Technology Development Award – Individual Achievement Award from the Ministry of Economic Affairs.
- Received the Forward-Looking Technology Innovation Award from the Ministry of Economic Affairs Industrial Technology Development Awards.
YEAR2008
- Listed as an Emerging Stock on the GreTai Securities Market (Taiwan OTC).
Stock code : 4911
YEAR2007
- The new drug development project “Phase II clinical evaluation of SR-T100 gel for the treatment of skin cancer” was approved for funding under the Industrial Technology Projects of the Ministry of Economic Affairs.
- The Southern Taiwan Science Park Administration approved the addition of cosmetic manufacturing to the company’s business scope.
- Obtained Department of Health approval to conduct Phase II clinical trials of SR-T100 gel, and initiated the trial at National Cheng Kung University Hospital.
YEAR2006
- Approved by the Institutional Review Board of National Cheng Kung University Hospital for human clinical trials in skin cancer, obtaining the ethical clearance certificate.
YEAR2005
- Obtained ISO 9001 international quality certification for R&D and manufacturing.
- Approved by the Joint Institutional Review Board for Chinese Medicine Clinical Trials (JIRB) and granted pilot clinical trial permits for SR-T100 in lung cancer and breast cancer.
YEAR2004
- Developed the product named “Xu-Jian-100”, registered the trademark, filed patents, and began mass production and sales.
- Completed installation of food plant facilities, passed start-up inspections for the food factory and research center, and commenced official operations.
- Commenced construction of cGMP manufacturing facilities for Western and Chinese medicines.
YEAR2003
- Commissioned the College of Medicine at National Cheng Kung University to conduct human clinical pharmacology and efficacy studies.
- Conducted animal efficacy evaluations for SR-100.
- The company’s “Chinese Herbal Bioactivity and Mechanism Research Center” passed the “R&D Management System” certification by the Chinese Management Science Society of the Republic of China.
- GMP pharmaceutical plant hardware certification obtained.
YEAR2002
- “G&E Pharmaceutical Co., Ltd.” was officially established.